Popular Targets for Bispecific Antibody Drugs Bispecific Antibody drugs have gained considerable popularity since the approval of blinatumomab. Currently, six bsAb drugs have been approved by the US FDA / EMA and over 180 are currently in clinical trials. BsAb simultaneously recognize different antigens or epitopes, resulting in a diverse range of therapeutic mechanisms. With a […]
